Clinical Trial Update: Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated the safety and efficacy of octreotide long-acting release (LAR) in treatment-naïve acromegaly patients and the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• Sandostatin LAR (octreotide)

Snippet

Sponsor: Novartis | Conditions: Acromegaly | Phase 3 | Status: COMPLETED